- Home
- CNTA vs ACLX Comparison
CNTA vs ACLX Comparison
Compare CNTA & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$27.73
N/A
Current Price
$114.34
Company Overview
Basic Information| Metric | CNTA | ACLX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CNTA | ACLX |
|---|---|---|
| Price | $27.73 | $114.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 15 |
| Target Price | $40.89 | ★ $115.85 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | N/A | $329.40 |
| Revenue Next Year | N/A | $151.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.60 | $47.86 |
| 52 Week High | $30.58 | $114.80 |
Technical Indicators
Market Signals| Indicator | CNTA | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 83.36 |
| Support Level | $21.93 | $66.66 |
| Resistance Level | $30.29 | N/A |
| Average True Range (ATR) | 1.18 | 0.38 |
| MACD | 0.14 | 0.10 |
| Stochastic Oscillator | 72.50 | 60.17 |
Price Performance
Historical Comparison CNTA
ACLX
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.